Immune cells in lymph nodes to predict immunotherapy benefit
Part of Cancer, Digestive system clinical trials.
This trial looks at whether certain cells in your lymph nodes (small immune glands) can predict how well PD-1 inhibitors (a type of immunotherapy) will work for your advanced or recurrent esophageal cancer. It aims to find a way to tailor treatment to each person.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with esophageal cancer that is either stage IV (advanced) or has come back after treatment.
- You are planning to receive treatment with a PD-1 inhibitor, a type of immunotherapy.
- You are generally able to care for yourself (ECOG performance status 0-2).
- You do not have an active autoimmune disease, uncontrolled heart issues, or serious infections like HIV, hepatitis B, or tuberculosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a way to predict whether immunotherapy (a treatment that helps your immune system fight cancer) will completely eliminate esophageal cancer before surgery. By examining lymph nodes, they hope to tailor treatment more personally.
This study is for people with lung or esophageal cancer who will receive immunotherapy (drugs that help your immune system fight cancer). The researchers want to find markers in your blood and tumor that can predict how well the treatment will work.
This study will test whether special imaging dyes can help doctors see a protein called PD-L1 on esophageal cancer tumors. This might help guide treatment by showing whether immunotherapy drugs are likely to work.
This trial studies a personalized approach to palliative care for people with advanced or recurrent esophageal cancer who are being treated with immunotherapy. It aims to improve quality of life and symptom management.
This Phase 3 trial tests whether adding a PD-1 medicine (sintilimab) to standard chemo-radiation before surgery improves outcomes for locally advanced esophageal squamous cell cancer. It may help by strengthening the immune response while shrinking the tumor before an operation.
This study uses an “immune indicator model” to help predict how well a PD-1 antibody (a cancer-fighting immune drug) works when combined with chemotherapy for stage IV esophageal squamous cell cancer. If you qualify, you receive the treatment and the researchers also look for immune-related signs that may explain who benefits most.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.